DSM bolsters lactase portfolio with new lactase enzyme
Royal DSM has launched its new Maxilact Super lactase enzyme. Advancing DSM’s portfolio of Maxilact lactases, Maxilact Super enables dairy manufacturers to create clean-tasting lactose-free and sugar-reduced dairy, while also help to cut hydrolysis by 33% and achieve optimal production efficiency. Moreover, Maxilact Super can be used in several dairy applications, from regular to organic and Verband Lebensmittel Ohne Gentechnik (VLOG). With this new enzyme innovation, lactose-free dairy producers can deliver the health appeal and sensory experience consumers expect in all applications.
As part of DSM’s range of Maxilact lactase solutions – including Maxilact Smart and Maxilact LGi – Maxilact Super is free from invertase and arylsulfatase, which can produce off-flavours and reduce stability during the shelf life of dairy products, thus ensuring a clan taste and high quality over a product’s lifecycle. Lactose-free manufacturers can also benefit from DSM to provide control and transparency throughout the production and distribution chain. Combined with DSM’s wider portfolio of cultures, probiotics, sugar reduction solutions, vitamins and minerals and hydrocolloids, lactose-free dairy producers have the tools they need to create innovative, consumer-centric solutions that stand out in today’s market.
Ben Rutten, global business manager for milk at DSM, said: “With 71% of consumers checking the labels of the products they purchase, combined with the ever-growing preference for lactose-free dairy and the sugar reduction trend that is here to stay, it is clear that prioritising health and authenticity is more important than ever for individuals today.
“DSM understands the challenges these diverse needs create for lactose-free dairy manufacturers, and with the innovative Maxilact Super solution, producers across the globe can efficiently deliver high-quality sugar-reduced and lactose-free dairy with next generation consumer appeal.”